Nintedanib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Explore 10 assets in Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03513484CT.gov Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nintedanib (this asset) | Northwestern University | P1 | CC · 43 |
| Gilteritinib | The First Affiliated Hospital of Soochow University | P3 | BB |
| Azacitidine | French Innovative Leukemia Organisation | P2 | BB |
| Cytarabine | First Affiliated Hospital of Zhejiang University | P3 | BB |
| Sorafenib | The First Affiliated Hospital of Soochow University | P3 | BB |
| Quizartinib | M.D. Anderson Cancer Center | P2 | BB |
| xy0206 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | P3 | BB |
| Daunomycin | Gruppo Italiano Malattie EMatologiche dell'Adulto | P3 | BB |
| Fludarabine | Astellas Pharma Global Development, Inc. | P2 | B |
+13 more in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort
Other indications for Nintedanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | — | P4 | BBB · 73 |
| Pulmonary Fibrosis | — | P3 | BB · 67 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nintedanib in Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nintedanib-acute-myeloid-leukemia-flt3-internal-tandem-duplication
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →